<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664599</url>
  </required_header>
  <id_info>
    <org_study_id>132/12487</org_study_id>
    <nct_id>NCT00664599</nct_id>
  </id_info>
  <brief_title>Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease</brief_title>
  <official_title>Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find if Rituximab can improve severe ocular lesions of
      Behcet's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test in a single blind randomized control study the efficacy of Rituximab versus
      combination of pulse cyclophosphamide and azathioprine. Both group receiving 0.5 mg/kg/daily
      prednisolone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory index for posterior uveitis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory index for retinal vasculitis, especially for edema</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Adjusted Disease Activity Index (TADAI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Behcet's Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytotoxics combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytotoxic Combination</intervention_name>
    <description>Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Behcet's Disease fulfilling the new International Criteria for Behcet's Disease

          -  Having active ocular lesions (posterior and/or retinal vasculitis)

          -  Resistant to cytotoxic drugs + prednisolone 0.5 mg/kg

        Exclusion Criteria:

          -  Visual acuity less than 1/10 on Snellen chart

          -  Antecedent of allergic reaction to any component of the therapeutic regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fereydoun Davatchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hormoz Shams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mozhgan Rezaipoor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farhad Shahram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheyda Chams-Davatchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bahar Sadeghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Research Center, Tehran University for Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Research Center, Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>April 27, 2008</last_update_submitted>
  <last_update_submitted_qc>April 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Fereydoun Davatchi, Head Rheumatology Research Center</name_title>
    <organization>Rheumatology Research Center, Tehran University for Medical Sciences</organization>
  </responsible_party>
  <keyword>Ocular lesions, Visual Acuity, Retinal Vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 18, 2010</submitted>
    <returned>September 10, 2010</returned>
    <submitted>November 19, 2010</submitted>
    <returned>December 14, 2010</returned>
    <submitted>February 20, 2011</submitted>
    <returned>March 21, 2011</returned>
    <submitted>June 2, 2012</submitted>
    <returned>July 5, 2012</returned>
    <submitted>November 4, 2015</submitted>
    <returned>December 9, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

